Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net loss	$ (2,835)	$ (2,502)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,397	1,321
Amortization of operating lease right-of-use assets	105	89
Amortization of deferred financing costs and debt discount	41	37
(Recoveries of) provision for doubtful accounts	(95)	13
Stock-based compensation expense	325	368
Loss on disposal of property and equipment	0	17
Changes in operating assets and liabilities:
Accounts receivable	626	448
Inventories	(103)	(1,198)
Prepaid expenses and other assets	16	85
Accounts payable	(326)	1,148
Accrued expenses and other liabilities	(12)	175
Deferred revenues	(247)	(257)
Operating lease liabilities	(95)	(97)
Net cash used in operating activities	(1,203)	(353)
Cash flows from investing activities:
Purchase of property and equipment	(1,406)	(679)
Cash paid in connection with TheraClear asset acquisition	0	(631)
Net cash used in investing activities	(1,406)	(1,310)
Net decrease in cash, cash equivalents and restricted cash	(2,609)	(1,663)
Cash, cash equivalents and restricted cash, beginning of year	6,795	12,586
Cash, cash equivalents and restricted cash, end of year	4,186	10,923
Cash and cash equivalents	2,825	10,923
Restricted cash	1,361	0
Supplemental disclosure of cash flow information:
Cash paid during the year for interest	241	160
Supplemental disclosure of non-cash operating, investing and financing activities:
Inventories acquired in connection with TheraClear asset acquisition	0	71
Intangible assets acquired in connection with TheraClear asset acquisition	0	10,182
Contingent consideration issued in connection with TheraClear asset acquisition	0	9,122
Common stock issued in connection with TheraClear asset acquisition	0	500
Transfer of property and equipment to inventories	45	0
Accrued payment of contingent consideration	14	$ 0
TheraClear Corporation [Member]
Supplemental disclosure of non-cash operating, investing and financing activities:
Accrued payment of contingent consideration	$ 14